Table 6.
Multivariate analysis, primary endpoint: 30-days mortality
| Multivariate analysis, primary endpoint: 30-days mortality (n = 45) | |||
|---|---|---|---|
| Variable | O.R. | 95 %-C.I. | p-value |
| HLP | 0.39 | (0.19 – 0.79) | 0.009 |
| AF | 3.33 | (1.49 – 7.47) | 0.003 |
| 3 V–CAD | 0.36 | (0.16 – 0.83) | 0.016 |
| COPD | 0.26 | (1.05 – 6.21) | 0.038 |
| PAD | 2.51 | (1.13 – 5.55) | 0.023 |
| Statin | 0.38 | (0.18 – 0.80) | 0.010 |
| Antiplatelet. | 1.99 | (0.95 – 4.17) | 0.070 |
| EF <40 % | 3.66 | (1.79 – 7.52) | <0,001 |
| Variable used in multivariable analysis: | |||
| Female | |||
| HT | |||
| pulm. HT | |||
| HLP | |||
| Diab. mellitus | |||
| AF | |||
| 3 V–CAD | |||
| LMS | |||
| COPD | |||
| PAD | |||
| Smoker | |||
| Crea >2 | |||
| Renal insuff. preop Crea <2 | |||
| CVA | |||
| Beta-blocker | |||
| Statin | |||
| Antiplatelet. | |||
| EF <40 % | |||
| IABP preop | |||
AF Atrial fibrillation, CVA cerebrovascular accident, HLP Hyperlipidemia, HT Hypertension, PAD peripherial artery disease, LMS left main stenosis